PH12013501528A1 - C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity - Google Patents

C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity

Info

Publication number
PH12013501528A1
PH12013501528A1 PH1/2013/501528A PH12013501528A PH12013501528A1 PH 12013501528 A1 PH12013501528 A1 PH 12013501528A1 PH 12013501528 A PH12013501528 A PH 12013501528A PH 12013501528 A1 PH12013501528 A1 PH 12013501528A1
Authority
PH
Philippines
Prior art keywords
inhibitory activity
hiv maturation
compounds
modified triterpenoids
hiv
Prior art date
Application number
PH1/2013/501528A
Other languages
English (en)
Inventor
Jie Chen
Yan Chen
Zheng Liu
Nicholas A Meanwell
Alicia Regueiro-Ren
Ny Sin
Sing-Yuen Sit
Jacob Swidorski
Brian Lee Venables
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PH12013501528A1 publication Critical patent/PH12013501528A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2013/501528A 2011-01-31 2012-01-27 C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity PH12013501528A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437893P 2011-01-31 2011-01-31
PCT/US2012/022852 WO2012106190A1 (en) 2011-01-31 2012-01-27 C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity

Publications (1)

Publication Number Publication Date
PH12013501528A1 true PH12013501528A1 (en) 2013-09-16

Family

ID=45567147

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2013/501528A PH12013501528A1 (en) 2011-01-31 2012-01-27 C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity

Country Status (25)

Country Link
US (3) US8846647B2 (enExample)
EP (1) EP2670765B1 (enExample)
JP (1) JP6001560B2 (enExample)
KR (1) KR101886467B1 (enExample)
CN (1) CN103429607B (enExample)
AR (1) AR085053A1 (enExample)
AU (1) AU2012212509B2 (enExample)
BR (1) BR112013019419A2 (enExample)
CA (1) CA2826113C (enExample)
CL (1) CL2013002185A1 (enExample)
CO (1) CO6751275A2 (enExample)
EA (1) EA022470B1 (enExample)
ES (1) ES2653847T3 (enExample)
IL (1) IL227678B (enExample)
MA (1) MA34909B1 (enExample)
MY (1) MY162186A (enExample)
PE (1) PE20141152A1 (enExample)
PH (1) PH12013501528A1 (enExample)
PT (1) PT2670765T (enExample)
SG (1) SG192144A1 (enExample)
TN (1) TN2013000321A1 (enExample)
TW (1) TWI628188B (enExample)
UY (1) UY33886A (enExample)
WO (1) WO2012106190A1 (enExample)
ZA (1) ZA201306546B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101665042B1 (ko) 2008-04-18 2016-10-11 리타 파마슈티컬스 잉크. 소염성 골격군을 포함하는 화합물 및 사용 방법
BRPI0911422B8 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
US8124799B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
JP5857068B2 (ja) 2010-12-17 2016-02-10 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーターとしてのピラゾリルおよびピリミジニル三環式エノン
PL2670764T3 (pl) * 2011-01-31 2016-02-29 Bristol Myers Squibb Co C-28 aminy zmodyfikowanych C-3 pochodnych kwasu betulinowego jako inhibitory dojrzewania HIV
TR201909788T4 (tr) 2011-03-11 2019-07-22 Reata Pharmaceuticals Inc C4-monometil triterpenoid türevleri ve bunların kullanım yöntemleri.
SG11201400331WA (en) 2011-09-21 2014-08-28 Bristol Myers Squibb Co Novel betulinic acid derivatives with antiviral activity
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
DK2841445T3 (en) 2012-04-27 2017-09-11 Reata Pharmaceuticals Inc 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONMETHYL, POLYMORPHE FORMS THEREOF AND PROCEDURES FOR USING IT
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
CA2881935A1 (en) * 2012-08-15 2014-02-20 Glaxo Group Limited Process for preparing a 1-(2-haolethyl)-4-piperidine carboxylate intermediate useful in the synthesis of umeclidinium bromide
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
BR112015005168A2 (pt) 2012-09-10 2017-08-15 Reata Pharmaceuticals Inc Derivados de c17-alcanodiila e alquenodiila de ácido oleanólico e métodos de uso dos mesmos
JP6186010B2 (ja) * 2013-02-06 2017-08-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hiv成熟阻害活性を有するc−19修飾トリテルペノイド類
BR112015019590A2 (pt) * 2013-02-25 2017-07-18 Bristol Myers Squibb Co derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
HUE051719T2 (hu) 2014-04-11 2021-03-29 Viiv Healthcare Uk No 4 Ltd Triterpenoidok HIV érésgátló aktivitással, amelyek a 3-helyzetben egy halogénalkil-szubsztituenst hordozó nem-aromás gyûrûvel helyettesítettek
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
EP3218388A1 (en) 2014-11-14 2017-09-20 VIIV Healthcare UK (No.5) Limited C17-aryl substituted betulinic acid analogs
RU2017118489A (ru) 2014-11-14 2018-12-14 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД Оксолупеновые производные
AU2016248068B2 (en) * 2015-04-14 2018-07-26 ViiV Healthcare UK (No.4) Limited Methods of producing an HIV maturation inhibitor
JP2018521093A (ja) 2015-07-28 2018-08-02 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Hiv感染を予防または治療するためのベツイン誘導体
KR20180028535A (ko) 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
WO2017025901A1 (en) * 2015-08-11 2017-02-16 Hetero Research Foundation Novel c28-analogues with c3-modifications of triterpene derivatives as hiv inhibitors
ES2865163T3 (es) 2015-09-23 2021-10-15 Reata Pharmaceuticals Inc Derivados de ácido oleanólico modificado en C4 para la inhibición de il-17 y otros usos
JP2018528231A (ja) 2015-09-24 2018-09-27 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Hiv成熟阻害活性を有する化合物
AU2016356335A1 (en) 2015-11-20 2018-05-31 ViiV Healthcare UK (No.4) Limited HIV maturation inhibitor formulations
EP3405474A1 (en) * 2016-01-20 2018-11-28 Glaxosmithkline Intellectual Property (No. 2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
US20190135857A1 (en) * 2016-06-30 2019-05-09 Viiv Healthcare Uk (No. 5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
WO2018044822A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
WO2019060051A1 (en) 2017-08-04 2019-03-28 Ardelyx, Inc. GLYCYRRHETINIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERKALIEMIA
JP6926939B2 (ja) * 2017-10-23 2021-08-25 東京エレクトロン株式会社 半導体装置の製造方法
JP6977474B2 (ja) * 2017-10-23 2021-12-08 東京エレクトロン株式会社 半導体装置の製造方法
EP4321164A3 (en) 2018-04-24 2024-04-17 ViiV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
PH12021551892A1 (en) 2019-02-07 2022-08-01 Ardelyx Inc Glycyrrhetinic acid derivatives for use in treating hyperkalemia
RS64915B1 (sr) 2019-02-11 2023-12-29 Hetero Labs Ltd Novi derivati triterpena kao inhibitori hiv-a
US12344631B2 (en) 2019-07-19 2025-07-01 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
GB2598300A (en) * 2020-08-21 2022-03-02 Univ Durham Cross-linking method and applications in bioconjugation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
CA2560266A1 (en) 2004-03-17 2005-09-29 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US8067620B2 (en) 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
CA2714049A1 (en) * 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17.beta. lupane derivatives
US9067966B2 (en) * 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
EA022393B1 (ru) * 2010-06-04 2015-12-30 Бристол-Майерс Сквибб Компани С-3 модифицированные производные бетулиновой кислоты в качестве ингибиторов созревания вич
ES2548905T3 (es) * 2010-06-04 2015-10-21 Bristol-Myers Squibb Company Amidas C-28 de derivados del ácido betulínico C-3 modificados como inhibidores de la maduración del VIH

Also Published As

Publication number Publication date
EP2670765A1 (en) 2013-12-11
EA022470B1 (ru) 2016-01-29
TWI628188B (zh) 2018-07-01
US20130035318A1 (en) 2013-02-07
US20160151387A1 (en) 2016-06-02
WO2012106190A1 (en) 2012-08-09
ZA201306546B (en) 2015-03-25
EA201391127A1 (ru) 2013-12-30
IL227678A0 (en) 2013-09-30
TW201309717A (zh) 2013-03-01
US20140343000A1 (en) 2014-11-20
AR085053A1 (es) 2013-08-07
IL227678B (en) 2018-04-30
UY33886A (es) 2012-07-31
JP6001560B2 (ja) 2016-10-05
CN103429607A (zh) 2013-12-04
AU2012212509B2 (en) 2016-01-21
EP2670765B1 (en) 2017-10-18
KR20140016279A (ko) 2014-02-07
PE20141152A1 (es) 2014-09-22
MY162186A (en) 2017-05-31
US8846647B2 (en) 2014-09-30
TN2013000321A1 (en) 2015-01-20
KR101886467B1 (ko) 2018-08-07
NZ614871A (en) 2014-06-27
SG192144A1 (en) 2013-08-30
AU2012212509A1 (en) 2013-09-19
JP2014503595A (ja) 2014-02-13
CL2013002185A1 (es) 2013-12-27
CN103429607B (zh) 2016-02-17
CA2826113A1 (en) 2012-08-09
CO6751275A2 (es) 2013-09-16
CA2826113C (en) 2018-09-04
ES2653847T3 (es) 2018-02-09
BR112013019419A2 (pt) 2019-12-03
PT2670765T (pt) 2018-01-08
MA34909B1 (fr) 2014-02-01

Similar Documents

Publication Publication Date Title
TN2013000321A1 (en) C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
MX2012013628A (es) Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
MX2012013703A (es) Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
MX2014013089A (es) Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
MX2015010354A (es) Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
MX2013008359A (es) Aminas de c-28 de derivados de acido betulinico modificado de c-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana.
EA201491531A1 (ru) C-3 циклоалкенил тритерпеноиды, ингибирующие созревание вич
MX2015010003A (es) Triterpenoides c-19 modificados, con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
MX2014012695A (es) Derivados de isoindolona.
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
GEP20186838B (en) 5-phenoxy-3h-pyrimidin-4-one derivatives and their usage as hiv reverse transcriptase inhibitors
IN2014DN09434A (enExample)
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
PH12013500005A1 (en) Indolizine derivatives, process for the preparation thereof and therapeutic use thereof
IN2015DN01119A (enExample)
MX2014002936A (es) Nuevos derivados de acido betulinico con actividad antiviral.
MY199668A (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
MX340574B (es) Imidazo pirazinas.
IN2015MN00411A (enExample)
MX2013008536A (es) Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana.
PH12018501640A1 (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
NZ622558A (en) Hiv replication inhibitors